$0.54
6.79% today
Nasdaq, Nov 20, 10:00 pm CET
ISIN
US22978P1066
Symbol
CUE

Cue Biopharma, Inc. Stock price

$0.58
-0.24 29.29% 1M
-0.13 17.98% 6M
-0.51 46.77% YTD
-0.50 46.28% 1Y
-2.55 81.46% 3Y
-12.12 95.43% 5Y
-11.05 95.01% 10Y
-11.05 95.01% 20Y
Nasdaq, Closing price Wed, Nov 19 2025
+0.00 0.03%
ISIN
US22978P1066
Symbol
CUE
Industry

Key metrics

Basic
Market capitalization
$45.7m
Enterprise Value
$28.7m
Net debt
positive
Cash
$18.7m
Shares outstanding
77.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.4 | 6.1
EV/Sales
4.0 | 3.8
EV/FCF
negative
P/B
3.5
Financial Health
Equity Ratio
54.4%
Return on Equity
-232.4%
ROCE
-236.4%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$7.1m | $7.5m
EBITDA
$-37.7m | -
EBIT
$-38.1m | $-40.0m
Net Income
$-37.7m | $-33.8m
Free Cash Flow
$-29.8m
Growth (TTM | estimate)
Revenue
-25.5% | -19.8%
EBITDA
16.6% | -
EBIT
16.5% | 3.8%
Net Income
15.5% | 16.9%
Free Cash Flow
22.2%
Margin (TTM | estimate)
Gross
-
EBITDA
-531.4% | -
EBIT
-536.7%
Net
-530.8% | -453.3%
Free Cash Flow
-420.0%
More
EPS
$-0.4
FCF per Share
$-0.4
Short interest
0.5%
Employees
41
Rev per Employee
$230.0k
Show more

Is Cue Biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Cue Biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Cue Biopharma, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Cue Biopharma, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Cue Biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
7.10 7.10
25% 25%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 17 17
11% 11%
237%
- Research and Development Expense 28 28
29% 29%
400%
-38 -38
17% 17%
-531%
- Depreciation and Amortization 0.38 0.38
10% 10%
5%
EBIT (Operating Income) EBIT -38 -38
17% 17%
-537%
Net Profit -38 -38
16% 16%
-531%

In millions USD.

Don't miss a Thing! We will send you all news about Cue Biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cue Biopharma, Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
Announced strategic collaboration and license agreement with ImmunoScape to develop breakthrough cell therapy approach for solid tumors – Company is entitled to receive upfront payments totaling $15M Announced strategic transition in leadership to further enable next stage of growth with disruptive autoimmune therapeutic candidates, most notably CUE-401, the Company's lead autoimmune asset BOST...
Neutral
GlobeNewsWire
14 days ago
Exclusive collaboration and license agreement focuses on advancing novel T cell therapy “Seed-and-Boost” approach exploiting the mechanism of the CUE-100 series of Immuno-STATs® Novel therapeutic approach is designed to enable in vivo expansion and activation of infused T cell receptor engineered T cells (TCR-Ts) to provide durability, tolerability and enhanced clinical benefit while reducing m...
Neutral
GlobeNewsWire
about 2 months ago
Usman Azam, M.D., is appointed President and Chief Executive Officer of Cue Biopharma, effective September 29, 2025 Daniel Passeri, Chief Executive Officer of Cue Biopharma, transitions to Strategic Advisor to provide ongoing support to the Company Cue Biopharma prioritizes autoimmune disease for next stage of growth with focus on advancing first-in-class tolerogenic biologic CUE-401 into the c...
More Cue Biopharma, Inc. News

Company Profile

Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO Daniel Passeri
Employees 41
Founded 2014
Website www.cuebiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today